Role of Dexamethasone in hospitalised patients in Covid-19.

A study was conducted to determine whether dexamethasone, a steroid, could reduce mortality in hospitalized COVID-19 patients by reducing lung damage caused by inflammation. The study involved randomly assigning patients to receive either dexamethasone or usual care. The primary outcome was 28-day mortality. The study found that patients who received dexamethasone had a lower mortality rate than those who received usual care, especially among patients who required respiratory support at the time of randomization. Specifically, patients who received invasive mechanical ventilation or oxygen alone had a lower mortality rate than those who received usual care. However, patients who did not require respiratory support did not show a significant difference in mortality between the two groups. The study was funded by various organizations and registered under ClinicalTrials.gov and ISRCTN.